Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225251 · ClinicalTrials.gov registry record · Phase 4
Wellbutrin XL for Dysthymic Disorder
A Phase 4 study, sponsored by St. Luke's-Roosevelt Hospital Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT00225251 is a Phase 4 study that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 18 participants.
The verdict
NCT00225251, a Phase 4 study, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a ten-week, double-blind study of Wellbutrin XL in outpatients with dysthymic disorder, a form of low-grade chronic depression. We hypothesize that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo.
Interventions
- OTHER Placebo
- DRUG bupropion XL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225251
The ClinicalTrials.gov registry entry for NCT00225251 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's-Roosevelt Hospital Center, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00225251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225251 about?
NCT00225251 is a clinical study titled "Wellbutrin XL for Dysthymic Disorder". This is a ten-week, double-blind study of Wellbutrin XL in outpatients with dysthymic disorder, a form of low-grade chronic depression. We hypothesize that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo.
What is the current status of trial NCT00225251?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2004-11. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00225251?
The interventions under investigation include: Placebo (OTHER), bupropion XL (DRUG).
Who is sponsoring clinical trial NCT00225251?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.